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Abstract
Background: Physical inactivity is a key contributor to the global burden of disease and disproportionately impacts
the wellbeing of people experiencing mental illness. Increases in physical activity are associated with improvements
in symptoms of mental illness and reduction in cardiometabolic risk. Reliable and valid clinical tools that assess
physical activity would improve evaluation of intervention studies that aim to increase physical activity and reduce
sedentary behaviour in people living with mental illness.
Methods: The five-item Simple Physical Activity Questionnaire (SIMPAQ) was developed by a multidisciplinary,
international working group as a clinical tool to assess physical activity and sedentary behaviour in people living
with mental illness. Patients with a DSM or ICD mental illness diagnoses were recruited and completed the SIMPAQ
on two occasions, one week apart. Participants wore an Actigraph accelerometer and completed brief cognitive
and clinical assessments.
Results: Evidence of SIMPAQ validity was assessed against accelerometer-derived measures of physical activity. Data
were obtained from 1010 participants. The SIMPAQ had good test-retest reliability. Correlations for moderatevigorous physical activity was comparable to studies conducted in general population samples. Evidence of validity
for the sedentary behaviour item was poor. An alternative method to calculate sedentary behaviour had stronger
evidence of validity. This alternative method is recommended for use in future studies employing the SIMPAQ.
Conclusions: The SIMPAQ is a brief measure of physical activity and sedentary behaviour that can be reliably and
validly administered by health professionals.
Keywords: Physical activity, Measurement, Mental illness, Exercise, Assessment, Sedentary behaviour
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Background
People with mental disorders experience high rates of comorbid chronic physical diseases including diabetes, obesity, and cardiovascular disease, contributing to an increased
mortality risk, regardless of psychiatric diagnosis [1, 2]. Although genetic factors contribute to overall cardiometabolic risk, the role of modifiable lifestyle behaviours,
such as physical inactivity and low physical fitness are becoming better recognised [3, 4]. Increasing physical activity
remains a cornerstone of metabolic and cardiovascular disease treatment and prevention in the general population
[5], with growing recognition that cardiorespiratory fitness
is inversely associated with all-cause mortality [6]. A 2019
Lancet Psychiatry Commission on protecting the physical
health of people with mental illness recommended that
physical activity be incorporated as part of routine psychiatric care regardless of diagnosis and across all treatment
settings [7]. In addition to the established physical health
benefits, physical activity can have both preventive and
treatment effects on psychiatric symptomatology for people
experiencing a range of mental disorders, including depression [8–10], anxiety disorders [11] and psychosis [12].
People with mental disorders have been shown to be significantly less physically active or less likely to meet international physical activity recommendations [4, 13–15].
Despite numerous calls for physical activity to be recognised as an integral component of routine psychiatric care
[16], including recognition in the recent WHO guidelines
[17], access to programs and integration within mental
health services remains ad-hoc in many jurisdictions, with
limited funding or resources available for implementation
in routine clinical care [18].
One barrier to the implementation of physical activity
programs within mental health settings is the lack of a
clinical tool to assess physical activity that enables risk
stratification based on activity levels. Similarly, without a
clinically feasible tool that can be used as part of routine
care, evaluating the effectiveness of interventions designed to increase physical activity is problematic. Currently methods used to assess physical activity vary in
cost, accuracy and feasibility [19].
Furthermore, no self-reported physical activity measures
have been developed specifically for people with mental illness and there is little consensus regarding the utility of
existing self-report questionnaires. A 2014 review of the
psychometric properties of physical activity assessment
tools identified 10 unique self-report questionnaires that
had been used in psychiatric populations with limited evidence for robust psychometric properties [20]. Arguably,
the most commonly used questionnaire for research purposes is the International Physical Activity Questionnaire
(IPAQ). The IPAQ was developed in 2003 specifically for
assessing population levels of total physical activity and
allowing for cross-country comparison [21, 22]. In 2006,

Page 2 of 12

the measurement properties of the IPAQ (short-form) in
35 people with schizophrenia who were living in the community, were found to be comparable to those in the general population [23]. The IPAQ has been used extensively
to measure physical activity in people diagnosed with mental health conditions [24] including as a measure of change
in clinical intervention studies. The validity of the IPAQ to
assess total sedentary behaviour has also been questioned,
with recent data suggesting that the IPAQ is unsuitable for
population level assessment of sitting time among individuals with schizophrenia [25]. Furthermore, a recent study
using data from the UK Biobank found that, although
people with schizophrenia self-reported the same physical
activity levels as the general population assessed using the
IPAQ, objective measures revealed that they were overall
less active than 80% of the general population, providing
evidence that existing self-report measures used in epidemiological studies of physical activity may fail to capture
lower physical activity levels in schizophrenia [26].
Use of the IPAQ in clinical settings may also be problematic for a number of reasons and differs from the
intended purpose of the tool which was to conduct population surveillance [22]. For example, physical activity lasting less than 10 min is not assessed using self-report
questionnaires such as the IPAQ, despite the potential
mental health benefits of such activity. The Second Edition of the Physical Activity Guidelines for Americans
published in 2018, note that any amount of physical activity has some health benefits, and removed the recommendation that only 10-min bouts of physical activity counted
towards meeting the guidelines [27]. Finally, while the
IPAQ assesses total levels of physical activity, it does not
differentiate between activities performed for the purposes
of structured exercise and physical activities performed as
part of daily life, which may also have important implications for mental health outcomes [28].
The measurement of physical activity in people with
mental illness presents unique challenges given diagnostic heterogeneity and differing symptom profiles among
psychiatric patients. For example, clinical variability in
mood may influence the ability to accurately respond to
self-report questionnaires, especially among people who
experience symptom fluctuations such as those with
rapid-cycling bipolar disorder. Psychotic symptoms,
grandiosity, and severe symptoms of depression and anxiety are also likely to influence the utility of self-report
measures. In addition, people with mental illness may
have unique barriers to accessing exercise facilities such
that hospitalization may result in restricted opportunities
to engage in physical activity. Alternatively, inpatient admission may allow access to customised physical activity
interventions in some settings. Given that physical activity is a key strategy to prevent cardio-metabolic disease
[17], a leading cause of premature mortality in people
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with mental illness, a measure appropriate for routine
clinical use in this population is required.
In order to ensure the accurate assessment of physical
activity across people with mental illness, we developed
a self-report, physical activity measurement tool, designed to be administered via interview. The Simple
Physical Activity Questionnaire (SIMPAQ) is a tool suitable for routine clinical use, and the current study was
conducted to determine the reliability and validity of the
SIMPAQ for assessing physical activity among inpatients
and outpatients experiencing mental illness.

Method
Approval was obtained from the Human Research Ethics
Committee (HREC) of UNSW Sydney, Australia (HC15586)
as the lead site. In addition, local ethics approval was sought
from each participating site as per local requirements. Details
of approving committees are provided under the Declaration
section below.
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Translation process

Translation was conducted according to the Principles of
Good Practice for the Translation and Cultural Adaptation
Process for Patient-Reported Outcomes (PRO) Measures,
as proposed by the International Society of Pharmacoeconomics and Outcomes (ISPOR) [30]. This process involved
ten steps including 1) preparation, 2) forward translation, 3)
reconciliation, 4) back translation, 5) back translation review, 6) harmonization, 7) cognitive debriefing, 8) review of
cognitive debriefing results and finalization, 9) proof reading, 10) publication on SIMPAQ website.
Participants

All participants were required to provide written informed
consent and be willing to wear an accelerometer for seven
days. Eligibility criteria also included: i) aged between 18
and 65 years, ii) a current inpatient or outpatient of one of
the treatment facilities identified as a SIMPAQ validation
study site and iii) met DSM-5 or ICD-10 criteria for any
mental disorder, excluding eating disorders.

SIMPAQ development

Study procedures

The SIMPAQ was iteratively developed between April 2014
and May 2016 by a multidisciplinary, international working
group with both clinical and research expertise (including
psychiatrists, psychologists, physiotherapists, exercise physiologists, and epidemiologists) regarding physical health care
interventions for people living with mental illness. The first
meeting was held in Padua, Italy, in April, 2014, to identify
the common challenges experienced when assessing physical activity among people with mental illness. At a subsequent meeting in July, 2015, held at the Institute of
Psychiatry, Psychology and Neuroscience in London (UK),
consensus agreement on the wording of the questions that
constitute the SIMPAQ was obtained.

Participants were approached by a researcher nominated
by the site coordinator who was not involved in the direct care of the patient. The researcher obtained written
informed consent. Data was collected from each participant during two face-to-face sessions, at least seven days
apart. Researchers involved in data collection included
either mental health or exercise professionals.

Participating Research sites

In addition to disseminating information about the project via the international workgroup, an editorial was
published in 2016 describing the proposed validation
process that helped to identify additional study sites
[29]. All study material and administration protocols
were available from the project website (www.simpaq.
org) when recruitment commenced in May 2016. All
sites were required to nominate a site coordinator and
sign an authorship agreement document. Along with
study material, site coordinators received a briefing from
investigators SR and PBW and were also in regular contact with the study coordinator RM. Eligibility criteria
for potential sites included willingness to recruit patients
meeting the inclusion criteria outlined below and availability of a site coordinator with expertise in either mental health or physical activity research.

Session 1

Demographic and descriptive information was collected
including assessment of symptoms and cognitive ability.
Participants completed the SIMPAQ (Time 1) and were
given a tri-axial accelerometer (Actigraph GT3x or
GT3x + (both models contain the same accelerometer
and processing method)) along with standardised instructions for wearing the device.
Session 2

Participants completed the SIMPAQ (Time 2) covering
the period of accelerometer wear time.
Data collection
Participant demographics and descriptive information

A standardised form was used to obtain demographic and
descriptive information including: age, sex, treatment setting (inpatient or other), years of completed education,
previous 7-day employment status (yes or no), previous 7day tobacco smoking status (yes or no), body mass index
(derived from measures of height [m] and weight [kg]).
Each country in which a site acquired SIMPAQ data
was assigned an income status (either high income or
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other) based on World Bank classification (www.worldbank.org).

Psychiatric diagnoses

Psychiatric diagnoses that applied to individual participants
based on medical records were recorded. It was recognized
that participants may meet criteria for more than one psychiatric diagnosis, and all diagnoses that applied to each participant were recorded. The standardised form asked
researchers to tick yes or no for the following diagnostic categories based on clinical diagnoses; schizophrenia spectrum
disorders, bipolar disorder, depressive disorders, anxiety disorders, obsessive-compulsive disorders, substance-related &
addictive disorders, neurocognitive disorders and other disorders. We identified individuals who were assigned a single
diagnostic category, and those with psychiatric co-morbidity.

Physical health conditions

The presence or absence (yes or no) of the following
physical health conditions at the time of assessment
were also recorded by the researcher; diabetes, high
cholesterol, high blood pressure, stroke and chronic pain
based on self-report and medical records.

Medication status

Researchers were asked to indicate whether participants
were currently prescribed the following classes of psychotropic medication (yes or no): antidepressant, antipsychotic, or mood stabilising medications.
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Cognitive functioning – Montreal cognitive assessment
(MoCA)

The Montreal Cognitive Assessment (MoCA) is a brief
screening tool used to assess cognitive functioning [32].
The MoCA assesses multiple cognitive domains including attention and concentration, executive functioning,
memory, language, visuo-constructional skills, conceptual thinking, calculation and orientation. Scores ranged
from 0 to 30 with scores of 26 or higher considered
within normal range. Given that many psychiatric syndromes are associated with cognitive impairment (e.g.
schizophrenia), we did not exclude participants scoring
less than 26. Results are reported for those with scores
above and below this threshold.
Simple physical activity questionnaire

The 5-item SIMPAQ required people being interviewed
to account for time spent in bed overnight (box 1), time
sedentary, including napping (box 2), time spent walking
(box 3), time spent exercising (box 4) and time engaged in
incidental activity (box 5), averaged over the past sevenday period (see Fig. 1). The sum of the hours recorded in
the five SIMPAQ boxes should add to approximately 24h, providing interviewers with an opportunity to clarify
with participants if significant under or over-reporting has
occurred (e.g. < 18 h or > 30 h of estimated time). For an
estimate of total self-reported moderate-vigorous physical
activity (MVPA) time, time spent walking (box 3) and exercising (box 4) were combined to provide total MVPA
(hours per week).
Percentage of 24-h period accounted for by SIMPAQ items

Symptom severity – DSM-5 self rated level 1 cross cutting
symptom measure

The 23-item DSM-5 Self-rated Level 1 Cross-cutting
Symptom Measure [31] was used to assess symptom severity. This measure consists of 23 questions that assess
13 psychiatric domains, including depression, anger,
mania, anxiety, somatic symptoms, suicidal ideation,
psychosis, sleep problems, memory, repetitive thoughts
and behaviours, dissociation, personality functioning,
and substance use [31]. Each question asks about how
much (or how often) the individual has been bothered
by the specific symptom during the past two weeks and
is rated on a 5-point scale (0 = none or not at all; 1 =
slight or rare, less than a day or two; 2 = mild or several
days; 3 = moderate or more than half the days; and 4 =
severe or nearly every day). We summed the total scores
across these domains and dichotomized the scores
around the median (20); lower symptom severity was defined as scores < 21; higher symptom severity was defined as scores > = 21.

The SIMPAQ was designed to capture activity over a
representative 24-h period from the previous 7-days. By
summing Boxes 1 through 5, the total hours accounted
for should equal approximately 24. To evaluate how well
this was achieved in the current study, we calculated the
fraction of time accounted for by using the following
formula:
sedentary time (box 2) + walking time (box 3) +
exercise
time (box 4) + incidental activity time (box 5)
______________________________________________
24 – time in bed (box 1)
Accelerometer – Actigraph GT3/x

Participants were asked to wear a tri-axial accelerometer
(Actigraph GT3x or GT3x+; ActiGraph LLC, Fort Walton
Beach, FL) on the right hip during waking hours for a period
of seven consecutive days to objectively assess physical activity. Accelerometers record raw acceleration data (at a sampling interval of 60 s epochs) that is converted into objective
activity measures such as step counts. Participants were
shown how to wear the device on the right hip using either a
belt clip or elastic waist band. After the seven-day period
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Fig. 1 Flow diagram of participants and analyses

participants returned the device and again completed the
SIMPAQ for comparison with Session 1 data. Prior to Actigraph devices being issued to participants they were initialised using the online portal. Each participant was setup in
CentrePoint and sex, age and weight were entered and the
device allocated to the subject. Accelerometry data were retrieved from the device using CentrePoint, a secure online
portal designed and distributed by Actigraph specifically for
multi-site study co-ordination. ActiLife v6.13.3 software was
used to extract data from CentrePoint and derive variables
to be used in the calculation of validity between accelerometry data and SIMPAQ items. Participant data were included
for analysis if at least eight hours of valid wear time were
available for at least four days. Non wear time was defined as
at least 60 min of consecutive zeroes, allowing for spike level
of 100 counts per minute [33]. We followed Freedson et al.
[34] to classify activity intensity using cutpoints for time
spent in sedentary (< 100 cpm), light (100–2019 cpm), moderate (2020–5998 counts/ min), and vigorous intensity (>
5999 cpm) activity [34].
Data analysis and cleaning

Non-parametric Spearman correlation coefficients were calculated as the primary measure of agreement between assessment time points (Session 1 and Session 2) (test-retest
reliability), and between the SIMPAQ data and accelerometer counts (evidence of validity). Agreement between the
SIMPAQ and accelerometer data was also assessed through

Bland-Altman mean-difference plots with 95% limits of
agreement. Intraclass correlation coefficients (ICC) along
with 95% confidence intervals were also calculated. Analyses
were conducted both with all valid data, and excluding outliers defined as those with SIMPAQ values that were greater
or less than 2.5 SD from the mean for that item. Results are
reported for the entire sample with available data and stratified by cognitive function as assessed by the MoCA and
psychiatric symptom severity derived from the DSM –
Cross-cutting tool. The sample were also stratified according
to specific diagnoses, and those with psychiatric comorbidity.
Income status, treatment setting, sex, age, body mass index
(BMI) and smoking status data were analysed separately.
Data were analysed using SPSS v24.
Reliability

Test re-test reliability was determined using Spearman
Rho correlation coefficients between SIMPAQ items at
Session 1 and Session 2. Given that the SIMPAQ asks
responders to report activity from the previous sevenday period, and the potential for hospital admission to
impact physical activity levels, only data from outpatients were utilised for reliability calculations.
Validity

To provide evidence for the validity of the SIMPAQ questionnaire, Spearman correlation coefficients were calculated
for MVPA as assessed by the SIMPAQ (box 3 + box 4) and
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MVPA as recorded by the accelerometer, and for sedentary
time (SIMPAQ box 2) against the accelerometer.

Results
Demographics

In total, data were collected from 1010 participants recruited from 23 countries. More than half of the sample of
participants were male (56%), from a high income country
(77%), between 25 and 54 years old (71%), current
smokers (60%), overweight or obese (60%; mean BMI =

27.1 SD 5.8), did not complete any paid employment in
the previous seven-day period (70%) and were recruited
from an inpatient facility (53%) (See Table 1). Overall,
there was significant psychiatric comorbidity (34%). Of
those with a single diagnosis, the most prevalent condition
was schizophrenia (23%) followed by depression (16%)
and bipolar disorder (14%). In total, 65% of the sample
(n = 648) scored greater than or equal to 26 on the MoCA
indicative of normal cognitive functioning. Regarding
medication usage, 56% of the sample were reported as

Table 1 Demographic characteristics
N
Total sample
Sex

Age group

Diagnosis

Psychotropic Medication

Cognitive ability

Treatment setting

%

1010
Male

561

56

Female

449

44

18–24 years

156

15

25–34 years

243

24

35–44 years

231

23

45–54 years

238

24

55–65 years

142

14

Psychiatric Comorbidity

343

33

Schizophrenia only

233

23

Bipolar disorder only

145

14

Depressive disorder only

159

16

Other

130

14

Antipsychotic

562

56

Antidepressant

477

47

Mood-stabiliser

290

29

Normal (> = 26)

648

65

impaired (< 26)

354

35

Inpatient

537

53

Outpatient

469

47

Smoking status

Smoker

611

60

Non-smoker

399

40

Body mass index (BMI)(kg/m2)

Underweight (< 18.5)

32

4

Desired (18.5–24.99)

305

36

Overweight (25–29.99)

267

31

Obese I (30–34.99)

171

20

Obese II (35–39.99)

50

6

Region

Country income status

Obese III (40–44.99)

27

3

Europe

507

50

Asia

249

25

Oceania

144

14

Americas

100

10

Africa

10

1

High income

777

77

Other (lower-upper middle income)

233

23
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In the overall sample, 70% of a standard 24-h period was
accounted for by the SIMPAQ. This did not vary within
any subgroups, with 70–80% of a 24-h time period consistently accounted for across region, country income status,
diagnostic group, cognitive ability, smoking status and age.

lower in those aged 55–65. Correlations were higher for
those who were obese compared to those who were normal
weight or overweight. Participants who were inpatients at
the time of assessment had lower correlations than those
who were outpatients. Those with psychiatric comorbidity
showed comparable correlations, while a higher correlation
was found in those with a diagnosis of depression in comparison with those with a diagnosis of schizophrenia. There
was no difference in correlations as a consequence of psychiatric symptom severity.
The Bland-Altman plot for MVPA (Fig. 2) indicates
less agreement between the two measures with higher
values of MVPA.

Reliability

Sedentary time

Test-retest repeatability was assessed in outpatients (see
Table 2). For these participants (n = 452), Spearman correlation coefficients were 0.75, p < 0.001 (box 1 – time spent in
bed), 0.69, p < 0.001 (box 2 – time spent sedentary), 0.76,
p < 0.001 (box 3 – time spent walking), 0.76, p < 0.001 (box 4
– time spent exercising) and 0.63, p < 0.001 (box 5 – time
spent in incidental activity), indicating acceptable to good
reliability.

The Spearman rho correlation coefficient was not statistically significant for the entire sample with available
data (rho = 0.02, n = 653; p = 0.6, ICC = 0.01, 95% CI −
0.15 to 0.15) (Table 4). For those with a higher MoCA
score, the Spearman rho correlation coefficient was 0.06
(n = 431) and for those with lower MoCA scores, − 0.06
(n = 215). Psychiatric comorbidity did not impact the
magnitude of the correlation and there was no difference
in correlations as a consequence of psychiatric symptom
severity. There was considerable variability in the observed correlation coefficients between SIMPAQ box 2
and sedentary time as assessed by the accelerometer.
The correlation was lower in high income countries, and
highest in Oceania and Asia. Correlations were similar
for smokers and non-smokers, and higher in those who
were older, overweight or obese and outpatients. The
Bland-Altman plot for sedentary time (Fig. 3) showed no
evidence of bias with higher or lower values of sedentary
time as assessed by the two measures.

receiving antipsychotic medication, 47% antidepressant
medication and 29% were prescribed mood-stabilisers.
Physical comorbidities were also recorded on the standardised assessment form with hypercholesterolemia (14%)
the most commonly reported, followed by chronic pain
(13%), hypertension (13%) and diabetes (6%).
Percentage of 24-h period accounted for by SIMPAQ

Evidence of validity

To assess validity, only participants with a minimum of
four valid days of accelerometer data were included. In
addition, for each individual SIMPAQ item, participants
who scored ±2.5SD from the mean were excluded (Fig. 1;
n’s for individual items range from n = 581 to n = 653).
Moderate-to-vigorous physical activity

The Spearman rho correlation coefficient between the two
measures for moderate-to-vigorous physical activity was
0.25 for the entire sample with available data (n = 617, p <
0.001; ICC = 0.23, 95% CI 0.01 to 0.34) (Table 3). For those
with higher MoCA scores, the Spearman rho correlation
coefficient was 0.32 (n = 401, p < 0.001) and for those with
lower MoCA scores, 0.10 (n = 210, p = 0.17). Validity was
lower in high-income countries, and this was most evident
in data from European sites (Table 3). High-income countries in Oceania had larger correlations than the full sample.
Larger correlations were observed in current smokers than
those who were non-smokers. Evidence of validity was

Alternative method for calculating sedentary time

Given that self-report questionnaires are likely to lead to
underestimates of sedentary behaviour, and given that
the average percentage of time accounted for by the
SIMPAQ as a percentage of 24-h (70–80%), we derived
an alternative method of scoring sedentary time from
the SIMPAQ. We summed the scores of time spent in
bed (box 1), time spent walking (box 3), time exercising
(box 4) and time incidental activity (box 5), which we

Table 2 Test-retest reliability of SIMPAQ items (Spearman Rho correlation coefficients) in outpatients
N

Box 1: Time in Bed

Box 2: Sedentary
time

Box 3: Walking
time

Box 4: Exercise
time

Box 5: Incidental
activity time

452

0.75

0.69

0.76

0.76

0.63

high income

323

0.8

0.68

0.59

0.69

0.58

other (lower-upper middle income)

131

0.7

0.49

0.74

0.84

0.81

Total outpatients
Outpatients by country income status

All p’s < 0.001
*N’s for treatment setting and country income status do not equal total sample due to missing demographic data
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Table 3 Correlations between MVPA assessed via the SIMPAQ
and accelerometry
N

Spearman rho

p

617

0.25

< 0.001

male

340

0.25

< 0.001

female

274

0.23

< 0.001

inpatient

346

0.09

0.11

outpatient

264

0.43

< 0.001

high income

480

0.12

0.01

other (lower-upper middle income)

134

0.26

0.002

normal (> = 26)

401

0.32

< 0.001

impaired (< 26)

210

0.10

0.17

Total sample
Sex

Treatment setting

Country income status

Cognitive ability

Diagnosis
psychiatric comorbidity

212

0.25

< 0.001

schizophrenia only

130

0.13

0.14

bipolar disorder only

78

0.23

0.04

depressive disorder only

112

0.33

< 0.001

*All participants with available data were included in each analysis

defined as non-sedentary time. We subtracted this figure
from 24-h to provide an alternative estimate of sedentary
behaviour. Evidence of validity for this alternative
method was statistically significant for the overall sample
(rho = 0.19, n = 581, p < 0.001; ICC = 0.29, 95% CI 0.17 to
4.0 (Table 5).

Discussion
This study examined the test-retest reliability and evidence of validity of a novel, brief, interview-based, selfreported physical activity measure, designed for routine
clinical use within psychiatric settings. In a large diverse
sample of psychiatric patients, ascertained across a variety of treatment settings and including a range of psychiatric diagnoses, with substantial representation from
low- and middle- income countries, we found that the
SIMPAQ was a reliable tool for assessing physical activity and sedentary behaviour. Evidence of validity for
MVPA was higher for outpatients than inpatients and
was comparable to that reported in general population
samples [35, 36] and in smaller cohorts of people with
mental illness [23].
In physical activity research, correlation coefficients between self-report and objective measures of physical activity of 0.3 are often reported as acceptable evidence of
validity [35–39]. This limited shared variance reflects the
challenges associated with both self-report questionnaires
and accelerometers when assessing physical activity in the
general population. Given that the correlations found for
the SIMPAQ were not substantially lower than those
deemed acceptable in general population samples, attests
to the utility of the SIMPAQ in people with mental illness
who can experience a range of additional challenges e.g.
psychiatric symptoms and cognitive impairment.
Correlations were lower for those with MoCA scores
below the usual cut-off indicative of cognitive impairment. We explicitly did not use the MoCA score as an
exclusion criterion considering that a number of psychiatric syndromes are characterised by cognitive impairment, e.g. schizophrenia. While the reliability of the

Fig. 2 Bland-Altman plot of absolute difference between MVPA assessed via SIMPAQ and accelerometery derived MVPA estimate
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Table 4 Correlations between sedentary behaviour assessed via
the SIMPAQ and accelerometry
N

Spearman rho

p

653

0.02

0.57

Male

360

0.08

0.12

Female

274

−0.08

0.19

inpatient

377

−0.08

0.14

outpatient

269

0.14

0.02

high income

518

0.04

0.38

other (lower-upper middle income)

132

0.11

0.23

normal (> = 26)

431

0.06

0.22

impaired (< 26)

215

−0.06

0.41

Total sample
Sex

Treatment setting

Country income status

Cognitive ability

Diagnosis
psychiatric comorbidity

220

0.03

0.71

schizophrenia only

140

0.04

0.66

bipolar disorder only

84

0.08

0.47

depressive disorder only

123

−0.03

0.72

*All participants with available data were included in each analysis

SIMPAQ was largely unaffected by cognitive capacity, it
is evident that those with lower MoCA scores had a
lower correlation with objectively measured MVPA.
Therefore, self-reported MVPA in those with higher
levels of cognitive impairment may be less accurately
reported.

For the overall sample, self-reported and objectively
assessed sedentary time were not significantly correlated.
Significant correlations were found for outpatients,
which may reflect the statistically significant lower
symptom severity (p < 0.001) and greater cognitive (p <
0.001) capacity of our outpatient sample. People living
with more severe mental illness may engage in high
levels of sedentary behaviour, and combined with some
degree of cognitive impairment, are likely to experience
particular difficulty in accurately estimating sedentary
time [40]. Additionally, the poor correlations between
the SIMPAQ and objective measure of sedentary behaviour can be in part explained by the fact that the Actigraph was waist-mounted and therefore is not a true
assessment of postural allocation (i.e. sitting or standing). Therefore low intensity activities performed while
sitting or standing may have been misclassified [41].
Given the known limitations of self-reported estimates
of sedentary behaviour in both the general population [41]
and in people living with mental illness [25, 26], we generated an alternative method for calculating sedentary time
using the SIMPAQ data (see Section 3.5). This involved
summing the scores of non-sedentary time estimates
(boxes 1, 3, 4 and 5) and subtracting this from 24 h. This
method therefore takes into account the tendency for
underreporting of sedentary behaviour and based on the
correlation analysis, appears to be a more valid estimate of
sedentary behaviour in the target population. Based on
these results, we recommend users of SIMPAQ adopt this
alternative scoring method to obtain more valid estimate
of sedentary behaviour, especially among inpatients and
those with high levels of cognitive impairment. Future

Fig. 3 Bland-Altman plot of absolute difference between sedentary time assessed via SIMPAQ and accelerometery derived estimate
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Table 5 Correlations between sedentary behaviour assessed via
the SIMPAQ and accelerometry, using the alternative SIMPAQ
scoring method
N

Spearman rho

p

581

0.19

< 0.001

Male

319

0.20

< 0.001

Female

259

0.18

< 0.01

Total sample
Sex

Treatment setting
inpatient

331

0.22

< 0.001

outpatient

243

0.18

< 0.01

high income

474

0.24

< 0.001

other (lower-upper middle income)

104

−0.14

0.16

normal (> = 26)

384

0.15

< 0.01

impaired (< 26)

191

0.25

< 0.001

psychiatric comorbidity

199

0.27

< 0.001

schizophrenia only

126

0.26

< 0.01

bipolar disorder only

74

0.04

0.76

depressive disorder only

112

0.09

0.32

Country income status

Cognitive ability

Diagnosis

*All participants with available data were included in each analysis

research should also aim to investigate the validity of the
SIMPAQ sedentary behaviour item using inclinometers.
The evidence of validity of the SIMPAQ as a tool to assess MVPA was comparable to other self-report measures
in the general population (e.g. [36]), and results were relatively consistent across diagnoses, sex and age. Unsurprisingly, we found different levels of correlations in different
settings and among different sub-groups within the sample. It should be noted that SIMPAQ was designed to be
used as a clinical tool administered by health professionals
regardless of training or expertise in exercise prescription
or assessment. In some of the participating centres, SIMPAQ was administered by exercise specialists (e.g. physical
therapists or exercise physiologists), whereas in other sites
SIMPAQ was administered by staff with primary mental
health qualifications (e.g. psychiatrists or psychiatric
nurses). There was no evidence of greater validity in settings where exercise professionals administrated the SIMPAQ versus mental health professionals. Given the diverse
backgrounds of people likely to administer the SIMPAQ,
the table in Item 4 of the tool deliberately allows for either
a brief summary, or a more comprehensive assessment of
exercise time (e.g. by completing the entire Table) if clinically indicated or the assessor has available time.
Limitations of this study include the opportunistic sampling method that does not reflect the global diagnostic
prevalence of different psychiatric disorders. While effort

was made to recruit a diverse sample of participants from
a range of settings including high and low income countries, there was an overrepresentation from high income,
English speaking countries. Regarding the development of
the SIMPAQ, in order to maximise clinical utility, we
aimed to ensure that administration time was minimised
and therefore comprehensive assessment of detailed aspects of physical activity such as the domain are not specifically evaluated. Another limitation is the use of
accelerometers as the objective measure of physical activity. While accelerometers are cheaper and more accessible
than other forms of objective measurement, they are not
without limitations including the inability to assess movement associated with non-ambulatory activity (e.g. cycling
and resistance training) [42].

Conclusion
In conclusion, we demonstrated that the SIMPAQ is a
reliable and valid tool to assess physical activity in
people living with mental illness. SIMPAQ does not require detailed training, identifies even small amounts of
activity which is useful in providing positive feedback to
patients participating in physical activity interventions, is
quick to administer and did not prove difficult for
people with mental health problems to complete. These
initial results are promising and suggest that the instrument is an appropriate tool for routine use in clinical
mental health services. Assessing and promoting physical activity as a component of care within mental health
services is a key means by which the physical and mental
health of this population can be improved.
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